16 April 2026
16 April 2026
The CYBORG study aims to assess the efficacy, safety and usability of the system.
Precision BioSciences has commenced site initiation activities and anticipates first patient screening to begin in Q2 2026.
Zai Lab will supply zoci while Boehringer Ingelheim will manage operations, with both companies retaining rights to their compounds.
GlycoNex expects to enrol patients in Japan and submit an IND in Taiwan by June 2026.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
